MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window [9]

Neurology

Volumn 66, Issue 7, 2006, Pages 1132-

  Mandava, Pitchaiah ^a   Anderson, Jane A ^a   Kent, Thomas A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; HEPARIN; ANTICOAGULANT AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ANTICOAGULATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; BRAIN ISCHEMIA; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NOTE; TIME;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BRAIN ISCHEMIA; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; TIME FACTORS;

EID: 33646096747     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000220161.34879.c1     Document Type: Letter

References (5)

1. Mitsias PD, Lu M, Silver B, et al. MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window. Neurology 2005;65:612-615.
2. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005;36:880-890.
3. Mandava P, Lick SD, Rahman MA, et al. Initial safety experience of abciximab and heparin for acute ischemic stroke. Cerebrovasc Dis 2005;19:276-278.
4. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose escalation study. Stroke 2000;31:601-609.
5. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998;97:5-9.